The U.S. Food and Drug Administration (FDA) has recorded an approval for ANDA083183, an injectable formulation of diphenhydramine hydrochloride.
Product details: the drug is administered by injection, presented as an injectable dosage form, with product number 001. It is not a reference drug and its marketing status is listed as discontinued. The active ingredient is diphenhydramine hydrochloride at a strength of 50 mg/mL.
The submission was an original (ORIG) filing, submission number 1, and received an approved (AP) status on 12 October 1973. The sponsor for this application is Hikma.
Regulatory UpdatesSep 24, 2026•1 min read
DIPHENHYDRAMINE HYDROCHLORIDE
FDA listed ANDA083183 for diphenhydramine hydrochloride injection (50 mg/mL) from sponsor Hikma; approved on 12 Oct 1973, marketing status discontinued.
Compiled by the PharmaCountry team · Source: FDA.gov
Ratings
(0)
(0)
(0)
(0)
(0)
More articles
View all insightsResearch & Reports
Global Finished Dosage Manufacturing Landscape 2026
Oct 5, 2026
Regulatory UpdatesKorea Korus hit with 1‑month manufacturing suspension over missing post‑marketing safety test
Sep 28, 2026
AnalysisPharma distributors set delivery cut‑offs ahead of Chuseok holiday (Sep 21‑23)
Sep 28, 2026
Leave your rating